TLDR Trump raised global tariffs to 15% after the Supreme Court blocked his emergency tariff powers Gold rose for a fourth straight session, hitting $5,170 on UTLDR Trump raised global tariffs to 15% after the Supreme Court blocked his emergency tariff powers Gold rose for a fourth straight session, hitting $5,170 on U

Gold Price Rises to $5,170 After Trump Announces 15% Global Tariff

2026/02/23 20:59
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

TLDR

  • Trump raised global tariffs to 15% after the Supreme Court blocked his emergency tariff powers
  • Gold rose for a fourth straight session, hitting $5,170 on U.S. futures
  • Trade deals with the EU, India, and Japan are now in doubt
  • A slowing U.S. economy and sticky inflation are pushing investors toward safe havens
  • Silver climbed 2.3% to $86.56/oz; hedge fund gold positions are at a near one-year low

Gold climbed for a fourth straight session on Monday after President Trump announced a new 15% global tariff, rattling markets and pushing investors toward safe-haven assets.

U.S. Gold Futures rose 1.8% to $5,170.19. Spot gold was up 0.8% at $5,148.66 an ounce as of Monday morning.

Micro Gold Futures,Apr-2026 (MGC=F)Micro Gold Futures,Apr-2026 (MGC=F)

The move followed a Supreme Court ruling that struck down Trump’s use of emergency powers to set import duties. Trump then turned to Section 122 of U.S. trade law, first announcing a 10% tariff, then raising it to 15% — the maximum allowed under that statute.

Trade Deals Now in Doubt

The court ruling threw several trade agreements into uncertainty. The EU’s trade chief said he would propose delaying ratification of a deal with Washington until there is more clarity on U.S. policy.

Indian officials postponed a planned trip to the U.S. A member of Japan’s ruling party described the situation as “a real mess.”

The uncertainty pushed investors away from risk assets. Money moved into gold and U.S. Treasuries as traders waited for more clarity on tariff scope, duration, and any potential legal challenges.

A weaker dollar added fuel to gold’s rise. The Bloomberg Dollar Spot Index fell 0.2% on Monday, following the same drop on Friday. A lower dollar makes gold cheaper for buyers holding other currencies.

Weak Economy and High Inflation Support Gold

U.S. economic data released last week gave investors more reason to hold gold. GDP grew at just 1.4% annualized in Q4, a sharp drop from the prior quarter.

At the same time, the Fed’s preferred inflation measure — the PCE index — showed prices rising 2.9% year-on-year in December. The core reading came in near 3.0%, still well above the Fed’s 2% target.

Slowing growth paired with elevated inflation is a combination that historically supports gold as both a store of value and an economic hedge.

Geopolitical tension between the U.S. and Iran also kept buyers active. Talks over Iran’s nuclear program are ongoing, but the U.S. has built up a large military presence in the region, keeping risk sentiment cautious.

Other Metals

Silver rose 2.3% to $86.56 per ounce. Platinum gained 0.3% to $2,164.60/oz. Copper futures were mostly flat.

CFTC data shows hedge fund net-long positions in gold futures have fallen to their lowest level in nearly a year, suggesting room remains for further buying pressure.

Spot gold was last recorded at $5,134.16 as of Monday afternoon Singapore time, with analysts warning that short-term volatility is likely as U.S. trade policy continues to develop.

The post Gold Price Rises to $5,170 After Trump Announces 15% Global Tariff appeared first on Blockonomi.

Market Opportunity
OFFICIAL TRUMP Logo
OFFICIAL TRUMP Price(TRUMP)
$3.085
$3.085$3.085
-1.43%
USD
OFFICIAL TRUMP (TRUMP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09